Brief: Molecular Templates Announces The FDA Removal Of Partial Clinical Hold In The Phase 1 Clinical Trial For MT-0169 And Focuses On Extramedullary Myeloma
01/06/2023 12:58
June 1 (Reuters) - Molecular Templates Inc MTEM.O :
* MOLECULAR TEMPLATES ANNOUNCES THE FDA REMOVAL OF PARTIAL
CLINICAL HOLD IN THE PHASE 1 CLINICAL TRIAL FOR MT-0169 AND
FOCUSES ON EXTRAMEDULLARY MYELOMA
Source text for Eikon: ID:nGNXd8Qmv
Further company coverage: MTEM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Molecular Templates
See all newsBrief: Molecular Templates Co & Affiliate Commenced Chapter 11 Cases As DIP
Brief: Molecular Templates's Eric E. Poma Resigns As CEO, CSO, Treasurer, And Interim CFO
Brief: Molecular Templates Announces Notice Of Delisting And Failure To Satisfy Continued Listing Rules
Brief: Molecular Templates Announces Receipt Of Expected Notification Of Deficiency From Nasdaq
Brief: Molecular Templates Approved Liquidation & Wind Up Through A Dissolution